Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/28/2012US8124124 Compressed tablet containing non-steroid antiinflammatory drug
02/28/2012US8124123 Controlled release azithromycin solid dosages forms
02/28/2012US8124122 Female hormone-containing patch
02/28/2012US8124121 Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
02/28/2012US8124120 Preparing and using crosslinked, water insoluble, hydrated hyaluronic acid gel particles; in vivo biostability and mechanical properties, usability; ease of injection through fine needles
02/28/2012US8124118 Composition comprising biodegradable hydrating ceramics for controlled drug delivery
02/28/2012US8124115 A stabilized antiseptic formulation having a higher acyclic alcohol concentration of 55-96% then commercially available produccts; also silicone and fluorosurfactants, polyoxyethylene glycol oradduct and ethyl cellulose stabilizer; skin and hands hygiene; surafaces;laundering; medical equipment
02/28/2012US8124105 Compositions, methods and kits relating to poxvirus subunit vaccines
02/28/2012US8124073 Targeting of glycoprotein therapeutics
02/28/2012US8124072 sufficient quantity of limonene suitable to solubilize said coenzyme Q-10 and carnitine; and an acceptable carrier
02/28/2012US8124064 In-vitro deposition evaluation method for identifying personal care compositions which provide improved deposition of benefit agents
02/28/2012US8124063 Method for moisturizing human skin using dihydroxypropyltri(C1-C3 alkyl) ammonium salts
02/28/2012US8124057 Propellant-based nanoparticulate dry powder aerosols and method of making
02/28/2012US8123707 Method and apparatus for connective tissue treatment
02/28/2012CA2637765C Benzamide and heteroarene derivatives
02/28/2012CA2514220C Ep4 receptor antagonists
02/28/2012CA2514019C Topical pharmaceutical and/or cosmetic dispense systems
02/28/2012CA2505139C Oromucosal formulation and process for preparing the same
02/28/2012CA2503361C Controlled-release compositions
02/28/2012CA2501335C Compounds capable of activating cholinergic receptors
02/28/2012CA2499665C Use of carbohydrates and compositions thereof for the treatment or prevention of diseases caused by imbalanced colon fermentation
02/28/2012CA2434938C Compositions of glucan and a monoclonal antibody which exhibit an enhancement of the anti tumor activity of the antibody
02/28/2012CA2392202C Constructs for delivery of therapeutic agents to neuronal cells
02/28/2012CA2356881C Compositions having improved delivery of actives
02/28/2012CA2333951C Method for treating neurodegenerative disorders
02/24/2012CA2770276A1 Preventing and curing beneficial insect diseases via plant transcribed molecules
02/24/2012CA2713465A1 Protein-bound tryptophan food composition
02/23/2012WO2012024682A1 Ship1 modulators and related methods
02/23/2012WO2012024670A2 Composition and methods for treating glioblastoma
02/23/2012WO2012024669A1 Method of drug detoxification
02/23/2012WO2012024637A2 Ethyl pyruvate compositions and methods
02/23/2012WO2012024630A1 Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
02/23/2012WO2012024620A2 Autotaxin inhibitors and uses thereof
02/23/2012WO2012024616A1 Methods of treating miild cognitive impairment (mci) and related discorders
02/23/2012WO2012024615A1 Nicotinic receptor compounds
02/23/2012WO2012024584A2 Oxysterol compounds
02/23/2012WO2012024583A2 Oxysterol compounds
02/23/2012WO2012024581A2 Oxysterol compounds
02/23/2012WO2012024559A1 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
02/23/2012WO2012024558A2 Light mediated regulation of protein dimerization
02/23/2012WO2012024519A2 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
02/23/2012WO2012024483A1 Synergistic fungicidal and algicidal compositions including 2-hydroxyphenylaldehyde and 2-hydroxyphenylketone heterocycloylhydrazones and copper
02/23/2012WO2012024478A2 Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt
02/23/2012WO2012024405A2 Curcumin compositions and uses thereof
02/23/2012WO2012024404A1 Diketones and hydroxyketones as catenin signaling pathway activators
02/23/2012WO2012024397A2 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
02/23/2012WO2012024376A1 Ep2 or ep4 agonists for treating corneal haze
02/23/2012WO2012024373A1 Compounds for the treatment of hepatitis c
02/23/2012WO2012024367A2 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
02/23/2012WO2012024363A2 Compounds and methods for the treatment or prevention of flaviviridae viral infections
02/23/2012WO2012024361A1 Commercial scale production methods for transdermal hormone formulations
02/23/2012WO2012024298A1 Ophthalmic formulations of squalamine
02/23/2012WO2012024293A2 Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
02/23/2012WO2012024287A1 Method of stabilizing and sterilizing peptides or proteins
02/23/2012WO2012024284A1 Lipidated immune response modifier compound compositions, formulations, and methods
02/23/2012WO2012024282A2 1,5-diphenyl-penta-1,4-dien-3-one compounds
02/23/2012WO2012024270A1 Nutritional composition comprising cereal beta-glucan and salacia extract
02/23/2012WO2012024196A2 A novel method for creating, suspending and stabilizing electronically modified reaction intermideates
02/23/2012WO2012024183A1 Spiroxazolidinone compounds
02/23/2012WO2012024179A1 Substituted amide derivatives as dgat-1 inhibitors
02/23/2012WO2012024161A1 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
02/23/2012WO2012024150A1 Oxadiazole inhibitors of leukotriene production
02/23/2012WO2012024083A1 Oxathiazine and dithiine oxides as inhibitors of sulfhydryl-dependent biomolecules
02/23/2012WO2012024072A1 Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
02/23/2012WO2012023955A1 Phospholipid depot
02/23/2012WO2012023865A1 Anti-microbial compositions
02/23/2012WO2012023660A1 Antiviral drug for avian and swine influenza and novel flu, obtained from cleistocalyx operculatus
02/23/2012WO2012023600A1 4-isopropyl-6-methoxyphenyl glucitol compound
02/23/2012WO2012023599A1 Process for production of triterpene alcohol
02/23/2012WO2012023597A1 Composition containing tetracyclic compound
02/23/2012WO2012023582A1 4-isopropylphenyl glucitol compound
02/23/2012WO2012023345A1 Method and composition for treating, preventing and diagnosing cancer containing cancer stem cells or derived therefrom
02/23/2012WO2012023301A1 Novel plant-derived immunostimulating agent
02/23/2012WO2012023291A1 Pharmaceutical composition for transcolonic absorption
02/23/2012WO2012023290A1 Rasef as tumor marker and therapeutic target for cancer
02/23/2012WO2012023288A1 Fam161a as a target gene for cancer therapy and diagnosis
02/23/2012WO2012023287A1 Suv420h1 and suv420h2 as target genes for cancer therapy and diagnosis
02/23/2012WO2012023285A1 Ehmt2 as a target gene for cancer therapy and diagnosis
02/23/2012WO2012023284A1 Lhx4 as a target gene for cancer therapy and diagnosis
02/23/2012WO2012023254A1 Novel anti-inflammatory metabolite derived from omega-3-type fatty acid
02/23/2012WO2012023146A1 A pharmaceutical composition of reformulated turmeric extract and a method thereof
02/23/2012WO2012023082A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - hydrocortisone acetate, and an antifungal agent - terbinafine hydrochloride, and a process to make it
02/23/2012WO2012023081A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - hydrocortisone acetate, and an antifungal agent - oxiconazole nitrate, and a process to make it
02/23/2012WO2012023080A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - fluticasone propionate, and an antifungal agent -terbinafine hydrochloride and a process to make it
02/23/2012WO2012023079A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, fluticasone propionate, oxiconazole nitrate and a process to make it
02/23/2012WO2012023078A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - dexamethasone acetate, and an antifungal agent - oxiconazole nitrate, and a process to make it
02/23/2012WO2012023077A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasol propionate, and an antifungal agent - oxiconazole nitrate, and a process to make it
02/23/2012WO2012022948A1 Treatment of liver cancer
02/23/2012WO2012022947A1 Nutritional compositions comprising chitin microparticles
02/23/2012WO2012022939A1 Treatment
02/23/2012WO2012022919A2 Nalbuphine-based formulations and uses thereof
02/23/2012WO2012022896A1 Pharmaceutical composition for the prevention of perioperative arterial hypotension in humans
02/23/2012WO2012022837A1 Transdermal compositions
02/23/2012WO2012022796A2 Novel combinations
02/23/2012WO2012022795A1 Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin b1 receptor
02/23/2012WO2012022794A1 Pyridazin derivatives as antagonists of the bradykinin b1 receptor
02/23/2012WO2012022793A1 New compounds
02/23/2012WO2012022792A1 2-(arylamino)-3h-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as mpges-1 inhibitors
02/23/2012WO2012022780A1 18-beta-glycyrrhetinic acid derivatives with anti-tumor activity
02/23/2012WO2012022776A1 Substituted thiopenes or furans as estrogen receptor ligands
1 ... 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 ... 7860